Community post

Technophage, a Portuguese clinical-stage biopharma company, announced today that the US FDA has granted Fast Track designation to TP-102, the company’s first phage cocktail, for the treatment of infected diabetic foot ulcers caused by three different bacteria (Pseudomonas aeruginosa, Staphylococcus aureus and/or Acinetobacter baumannii).